| dbo:abstract
|
- Apalutamid (im Englischen Apalutamide) ist ein orales, nicht-steroidales Antiandrogen (NSAA), welches zur Behandlung von Prostatakarzinomen eingesetzt wird. (de)
- Apalutamide, sold under the brand name Erleada among others, is a nonsteroidal antiandrogen (NSAA) medication which is used in the treatment of prostate cancer. It is specifically indicated for use in conjunction with castration in the treatment of non-metastatic castration-resistant prostate cancer (NM-CRPC). It is taken by mouth. Side effects of apalutamide when added to castration include fatigue, nausea, abdominal pain, diarrhea, high blood pressure, rash, falls, bone fractures, and an underactive thyroid. Rarely, it can cause seizures. The medication has a high potential for drug interactions. Apalutamide is an antiandrogen, and acts as an antagonist of the androgen receptor, the biological target of androgens like testosterone and dihydrotestosterone. In doing so, it prevents the effects of these hormones in the prostate gland and elsewhere in the body. Apalutamide was first described in 2007, and was approved for the treatment of prostate cancer in February 2018. It was the first medication to be approved specifically for the treatment of NM-CRPC. (en)
- L'apalutamide est une molécule de la classe des antiandrogènes non stéroïdiens, en cours de test dans le traitement du cancer de la prostate. (fr)
|
| rdfs:comment
|
- Apalutamid (im Englischen Apalutamide) ist ein orales, nicht-steroidales Antiandrogen (NSAA), welches zur Behandlung von Prostatakarzinomen eingesetzt wird. (de)
- L'apalutamide est une molécule de la classe des antiandrogènes non stéroïdiens, en cours de test dans le traitement du cancer de la prostate. (fr)
- Apalutamide, sold under the brand name Erleada among others, is a nonsteroidal antiandrogen (NSAA) medication which is used in the treatment of prostate cancer. It is specifically indicated for use in conjunction with castration in the treatment of non-metastatic castration-resistant prostate cancer (NM-CRPC). It is taken by mouth. Apalutamide was first described in 2007, and was approved for the treatment of prostate cancer in February 2018. It was the first medication to be approved specifically for the treatment of NM-CRPC. (en)
|
